TMCnet News
Principia Biopharma Appoints Shao-Lee Lin, M.D., Ph.D. to Board of DirectorsSOUTH SAN FRANCISCO, Calif., April 18, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced the appointment of industry veteran Shao-Lee Lin, M.D., Ph.D., a noted immunologist, rheumatologist, and allergist with significant biopharmaceutical development experience, to its Board of Directors. Dr. Lin is currently Executive Vice President, head of Research and Development and Chief Scientific Officer of Horizon Pharma plc., with past corporate experiences at AbbVie Inc., Gilead Sciences, Inc., and Amgen Inc. “Shao-Lee’s expertise in the medical field comes at a great time for Principia as we continue to develop PRN1008 in both a Phase 3 trial in patients with pemphigus, and a Phase 2 trial in patients with immune thrombocytopenia,” said Martin Babler, Principia’s Chief Executive Officer. “Shao-Lee has extensive experience in developing new medicines, overseeing global development organizations, and leading R&D teams across multiple therapeutic areas.” Dr. Lin is an accomplished pharmaceutical executive, physician and scientist with more than 20 years of academic and clinical research experience. Prior to her current role at Horizon Pharma, Dr. Lin was Vice President, Therapeutic Areas, Development Excellence and International Development at AbbVie. In that role, she led immunology, virology, neuroscience and general medicine across commercial products and pipeline candidates as well as international development across all therapeutic areas. Prior to AbbVie, Dr. Lin was Vice President, Inflammation and Respiratory Development at Gilead Sciences. She also held leadership poitions in immunology and other therapeutic areas while at Amgen. Dr. Lin received her medical degree and doctorate at The Johns Hopkins University School of Medicine and completed fellowships and post-doctoral work in rheumatology, allergy and immunology at the University of California San Diego and The Scripps Clinic and Research Institute. She received her undergraduate degree in biochemistry and chemical engineering from Rice University. Dr. Lin has also been faculty as a Clinical Scholar at The Rockefeller University, and adjunct faculty at Cornell, UCLA, Stanford and Northwestern medical schools. About Principia Biopharma Forward-Looking Statements Investor Contact Christopher Chai, CFO [email protected] Media Contact Denise Powell [email protected] |